Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Leuven Research Opens New Pathway… >

Leuven Research Opens New Pathway for the Treatment of Alzheimer's Disease

Published: December 3, 2012.
Released by VIB (the Flanders Institute for Biotechnology)  

Scientists from VIB and KU Leuven have discovered a new target molecule for the development of a treatment against Alzheimer's disease. There is currently no cure for this disease. Many candidate drugs fail because they also target proteins essential to life. This discovery from Leuven could form a target for a treatment against Alzheimer's disease with fewer side effects and that suppresses the very first symptoms of the disease. This research will be published in the leading journal Nature Medicine.

Alzheimer's Disease

Alzheimer's Disease is the most common form of dementia in the West. The damage to memory and mental function causes one of the most terrifying clinical pictures. The current drugs for Alzheimer patients support memory for a short time, but they do not stop the death of brain cells. Recent insights have shown that Alzheimer's disease causes biochemical changes in the brain many years before the symptoms of dementia are present. It is very important to develop drugs that can be taken at this early stage in order to prevent the disease.

The ɣ-secretase complex

Many candidate drugs have an effect on the ɣ-secretase complex. This complex cuts proteins at specific sites and plays an important role in the development of amyloid plaques, a pathological hallmark in of the brains of Alzheimer patients. Aberrant and excessive cleavage of the amyloid precursor protein by the y-secretase complex results in the accumulation and deposition of the β-amyloid protein in amyloid plaques.

However, the ɣ-secretase complex is also involved in cleavage of a series of other proteins essential to life. As a result, many candidate drugs that act on the ɣ-secretase complex produce toxic side effects.

GPCRs and β-arrestin

GPCRs are a family of proteins that serve as the targets of the majority of all currently marketed drugs. The Nobel Prize in Chemistry for 2012 was awarded to Dr. Robert Lefkowitz and Dr. Brian Kobilka for their groundbreaking work in this field and the many medical applications of this knowledge. It is known that GPCRs also play a role in the development of Alzheimer's disease, but it is not yet clear how GPCRs regulate the ɣ-secretase complex.

β-arrestins are a family of proteins that classically block or limit GPCR activation; however, it has been recently appreciated that β-arrestins also have additional functions. Therefore, Amantha Thathiah set up a study under the supervision of Bart De Strooper to examine the involvement of β-arrestins in the development of Alzheimer's disease.

The scientists succeeded for the first time in demonstrating that β-arrestin 2 plays a role in regulation of the ɣ-secretase complex function and in the development of Alzheimer's disease in an Alzheimer's disease mouse model. More specifically, β-arrestin 2 interacts with two GPCRs that are known to play a role in the development of Alzheimer's disease. Moreover, expression of β-arrestin 2 is also elevated in individuals with Alzheimer's disease.

Impact of the research

This research opens a new pathway for the treatment of Alzheimer's disease. β-arrestin 2 inhibition could be beneficial in prevention of the adverse side effects currently associated with γ-secretase inhibition. Therefore, this study provides a previously unexplored avenue for the development of a treatment that can act at a very early stage of Alzheimer's disease.




The above story is based on materials provided by VIB (the Flanders Institute for Biotechnology).

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Alzheimer 
11/20/12 
★★★★ 
Discovery of Molecular Pathway of Alzheimer's Disease Reveals New Drug Targets
The discovery of the molecular pathway that drives the changes seen in the brains of Alzheimer's patients is reported today, revealing new targets for drug discovery that could be …
Alzheimer 
7/5/10 
Plasma Protein Appears to Be Associated with Development And Severity of Alzheimer's Disease
Higher concentrations of clusterin, a protein in the blood plasma, appears to be associated with the development, severity and progression of Alzheimer's disease, according to a report in the …
Patients 
12/8/14 
Researchers at Mainz University Explore New Approach for Treating Alzheimer's Disease
It is estimated that about 35 million people worldwide currently suffer from dementia and it is expected that the number will increase to 135 million by the year 2050. …
Stop 
7/1/13 

UCLA Discovery Sheds Light on Why Alzheimer's Meds Rarely Help
Protein 
5/20/13 
Molecular Trigger for Alzheimer's Disease Identified
Researchers have pinpointed a catalytic trigger for the onset of Alzheimer's disease – when the fundamental structure of a protein molecule changes to cause a chain reaction that leads …
Astrocytes 
12/11/12 
Kentucky Team Inhibits Alzheimer's Biomarkers in Animal Model by Targeting Astrocytes
LEXINGTON, Ky. (Dec. 10, 2012) — A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could …
Disease 
7/25/12 
New Research Determines How a Single Brain Trauma May Lead to Alzheimer's Disease
BOSTON (July 24, 2012, 5:00PM EST)—A study, performed in mice and utilizing post-mortem samples of brains from patients with Alzheimer's disease, found that a single event of a moderate-to-severe …
Alzheimer 
5/25/10 
Protein Regulates Enzyme Linked to Alzheimer's Disease
BOSTON (May 25, 2010) — Researchers at Tufts University School of Medicine have zeroed in on a protein that may play a role in the progression of Alzheimer's disease. …
Neu1 
12/3/13 
Gene Therapy Bolsters Enzyme Activity to Combat Alzheimer's Disease in Mice
(MEMPHIS, Tenn.—December 3, 2013) St. Jude Children's Research Hospital scientists have identified an enzyme that can halt or possibly even reverse the build-up of toxic protein fragments known as …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile